Absence of Evidence for Pervasive CAR19 Driven T-Cell Lymphomagenesis Revealed By Comprehensive Genomic Profiling of an Index Tumor.

Despite the success of chimeric antigen receptor (CAR) T-cell therapies, concerns over toxicity remain. Recent reports indicate development of post-infusion T-cell lymphoma (TCL) after CAR therapy. There is minimal data regarding TCL development after commercially available CAR19 products. We analyzed 234 cases of lymphoma (189 LBCL, 20 FL, 25 MCL) treated with commercial CAR19 (100% axi-cel and brexu-cel). One patient, a 59-year-old female with CD19+/CD20+/EBV+ DLBCL, developed a post-infusion CD3+/CD4+/EBV+ T-cell lymphoma (Fig 1) diagnosed in the bone marrow (BM) on day 55 (D55).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mark P. Hamilton, Takeshi Sugio, Troy Noordenbos, Shuyu Shi, Max Diehn, Dita Gratzinger, David B. Miklos, Ash A. Alizadeh, Zinaida Good Tags: LBA-2 Source Type: research